Ciclesonide: A novel inhaled corticosteroid for the treatment of persistent asthma - A pharmacologic and clinical profile

Therapy

Volumn 2, Issue 2, 2005, Pages 167-178

  Berger, William E ^a  

^a Allergy & Asthma Associates of Northern California   (United States)

Author keywords

Asthma; Ciclesonide; Desisobutyrylciclesonide; Efficacy; Pharmacokinetics; Safety

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; DESISOBUTYRYLCICLESONIDE; DEXAMETHASONE; DRUG METABOLITE; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE; MOMETASONE FUROATE; PLACEBO; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DYSPHONIA; EYE DISEASE; GROWTH RETARDATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LONG TERM CARE; LUNG PARENCHYMA; METABOLIC BONE DISEASE; METERED DOSE INHALER; MILD PERSISTENT ASTHMA; MODERATE PERSISTENT ASTHMA; NEUROENDOCRINE DISEASE; NONHUMAN; PATIENT COMPLIANCE; PHARYNGITIS; REVIEW; SEVERE PERSISTENT ASTHMA; SKIN MANIFESTATION; SYSTEMIC DISEASE; THRUSH;

EID: 16244369155     PISSN: 14750708     EISSN: None     Source Type: Journal    
DOI: 10.1586/14750708.2.2.167     Document Type: Review

References (74)

1. Mannino DM, Homa DM, Akinbami LJ, Moorman JE, Gwynn C, Redd SC. Surveillance for asthma - United States, 1980-1999. MMWR Surveill. Summ. 51(1), 1-13 (2002).
2. GINA: Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. National Institutes of Health, National Heart, Lung and Blood Institute. Revised 2002 (2002).
3. Redd SC. Asthma in the United States: burden and current theories. Environ. Health Perspect. 110(Suppl. 4), 557-560 (2002).
4. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 59(5), 469-478 (2004).
5. Allen DB, Bielory L, Derendorf H, Dluhy R, Colice GL, Szefler SJ. Inhaled corticosteroids: past lessons and future issues. J. Allergy Clin. Immunol. 112(Suppl. 3), S1-40 (2003).
6. NIH. National Institutes of Health. Guidelines for the diagnosis and management of asthma, 1997: updated in 2002. (2002).
7. Rohatagi S, Appajosyula S, Derendorf H et al. Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J. Clin. Pharmacol. 44(1), 37-47 (2004).
8. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir. Med. 91(Suppl. A), 22-28 (1997).
9. Corren J, Berkowitz R, Murray JJ, Prenner B. Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma. Int. J. Clin. Pract. 57(7), 567-572 (2003).
10. Postma D, Sevette C, Martinat Y, Schlösser N, Aumann J, Kafé H. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur. Respir. J. 17, 1083-1088 (2001).
11. Cochrane GM. Compliance and outcomes in patients with asthma. Drugs 52(Suppl. 6), 12-19 (1996).
12. Campbell L. Once-daily inhaled corticosteroids in mild to moderate asthma: improving acceptance of treatment. Drugs 58(Suppl. 4), 25-33 (1999).
13. Pedersen S, O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 52(Suppl. 39), 1-34 (1997).
14. Kelly HW, Nelson HS. Potential adverse effects of the inhaled corticosteroids. J. Allergy Clin. Immunol. 112(3), 469-478 (2003).
15. Passalacqua G, Albano M, Canonica GW et al. Inhaled and nasal corticosteroids: safety aspects. Allergy 55, 16-33 (2000).
16. Lipworth BJ, Seckl JR. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax 52(5), 476-482 (1997).
17. Allen DB. Sense and sensitivity: assessing inhaled corticosteroid effects on the hypothalamic-pituitary-adrenal axis. Ann. Allergy Asthma Immunol. 89(6), 537-539 (2002).
18. Lipworth B. Systemic adverse effects of inhaled corticosteroid therapy: a systemic review and meta-analysis. Arch. Intern. Med. 159, 941-955 (1999).
19. Schmier J, Leidy NK, Gower R. Reduction in oral corticosteroid use with mometasone furoate dry powder inhaler improves health-related quality of life in patients with severe persistent asthma. J. Asthma 40(4), 383-393 (2003).
20. Derom E, Van De Velde V, Marissens S, Engelstätter R, Vincken W, Pauwels RA. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5′ monophosphate in asthmatic patients. Pulm. Pharmacol. Ther. (In Press).
21. Biberger C, von Behren V, Malek R et al. Efficacy and safety of ciclesonide compared with budesonide in asthma patients: A randomized 12-week study. Am. J. Respir. Crit. Care Med. 167(7), A771 (2003).
22. Boulet L, Engelstätter R, Magyar P, Timar M, Knight A, Fabbri L. Ciclesonide is at least as effective as budesonide in the treatment of patients with bronchial asthma. Am. J. Respir. Crit. Care Med. 167(7), A771 (2003).
23. Kaliner M, White M, Chervinsky P et al. Ciclesonide, a novel inhaled corticosteroid, does not suppress hypothalamic-pituitary-adrenal axis function. Allergy Clin. Immunol. Int. (Suppl. 1), (2003) Abstract 17-1.
24. Timmer W, Weinbrenner A, Hüneke D et al. Repeated inhalation of the new topical steroid ciclesonide does not lead to adrenal suppression in healthy subjects. Am. J. Respir. Crit. Care Med. 161(Suppl. 3), A776 (2000).
25. Szefler S, Herron J, Lloyd M et al. High doses of the novel inhaled steroid ciclesonide have no effect on HPA-axis function in patients with moderate-to-severe persistent asthma. J. Allergy Clin. Immunol. 111(2), S216 (2003) Abstract 590.
26. Weinbrenner A, Hüneke D, Zschiesche M et al. Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J. Clin. Endocrinol. Metab. 87(5), 2160-2163 (2002).
27. Bernstein J, Noonan M, Rim C et al. Ciclesonide has minimal oropharyngeal side effects in the treatment of patients with moderate-to-severe asthma. J. Allergy Clin. Immunol. 113(Suppl. 2), S113 (2004).
28. Bethke T, Boudreau RJ, Hasselquist B et al. High lung deposition of ciclesonide in 2D- and 3D-imaging. Eur. Respir. J. 20(Suppl. 38), S109 (2002).
29. Dietzel K, Engelstätter R, Keller A. Ciclesonide: an on-site activated steroid. Prog. Respir. Res. 31, 91-93 (2001).
30. Rohatagi S, Arya V, Zech K et al. Population pharmacokinetics and pharmacodynamics of ciclesonide. J. Clin. Pharmacol. 43(4), 365-378 (2003).
31. 14C] ciclesonide after oral and intravenous administration to healthy subjects. Clin. Pharmacokinet. 43(7), 479-486 (2004).
32. Stoeck M, Riedel R, Hochhaus G et al. In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide. J. Pharmacol. Exp. Ther. 309(1), 249-258 (2004).
33. Nave R, Drollmann A, Meyer W, Zech K. In vivo epimeric stability of ciclesonide. Am. J. Respir. Crit. Care Med. 167(7), A771 (2003).
34. Nave R, Hummel R, Wohlsen A, Herzog R, Zech K. The active metabolite of ciclesonide, des-isobutyryl ciclesonide, forms highly lipophilic fatty acid conjugates in precision-cut rat lung slices. Am. J. Respir. Crit. Care Med. 169(7), A791 (2004).
35. Nave R, Sättele N, Meyer W, Fuhst R, Zech K. Formation of fatty acid conjugates of ciclesonide-active principle in the rat lung after 4-week inhalation of ciclesonide. Am. J. Respir. Crit. Care Med. 167(7), A771 (2003).
36. Kelly HW. Establishing a therapeutic index for the inhaled corticosteroids: part I pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids. J. Allergy Clin. Immunol. 102(4 Pt 2), S36-S51 (1998).
37. Derendorf H, Hochhaus G, Meibohm B, Möllmann H, Barth J. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J. Allergy Clin. Immunol. 101(4 Pt 2), S440-S446 (1998).
38. Harding SM. The human pharmacology of fluticasone propionate. Respir. Med. 84(Suppl. A), 25-29 (1990).
39. Richter K, Kanniess F, Biberger C, Nave R, Magnussen H. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J. Clin. Pharmacol. 45(2), 146-152 (2005).
40. Nave R, Zech K, Bethke T. Oropharyngeal deposition of inhaled ciclesonide and budesonide in healthy subjects. J. Allergy Clin. Immunol. 111(2), A606 (2003).
41. Rohatagi S, Derendorf H, Zech K, Nave R, Banerji D. PK/PD of inhaled corticosteroids: The risk/benefit of inhaled ciclesonide. J. Allergy Clin. Immunol. 111(2), S218 (2003) Abstract 598.
42. Edsbäcker S. Pharmacological factors that influence the choice of inhaled corticosteroids. Drugs 58(Suppl. 4), 7-16 (1999).
43. Drollmann A, Hasselquist B, Boudreau R et al. Ciclesonide shows high lung deposition in 2D and 3D-imaging. Am. J. Respir. Crit. Care Med. 165(8), A188 (2002).
44. 99mTc-labelled ciclesonide administered via the HFA-MDI to asthma patients. Eur. Respir. J. 24(Suppl. 48), Abs. (2004).
45. Drollmann A, Nave R, Steinijans V, Bethke T, Baumgaertner E. Equivalent pharmacokinetics of the active metabolite of ciclesonide with and without use of a spacer for inhalation. J. Allergy Clin. Immunol. 113(2), S120 (2004).
46. Rohatagi S, Luo Y, Shen L et al. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, Ciclesonide. Am. J. Ther. (In press).
47. Mutch E, Nave R, Zech K, Williams F. Esterases involved in the hydrolysis of ciclesonide in human tissues. Eur. Respir. J. 22(Suppl. 45), P1749 (2003).
48. Nave R, Fisher R, Zech K. In vitro metabolism of ciclesonide in the human lung and liver as determined by use of precision-cut tissue slices. Am. J. Respir. Crit. Care Med. 167(7), A771 (2003).
49. Hall M, Peet C, Boddington T, Enos T, Nave R, Zech K. Enzymology of the human hepatic metabolism of ciclesonide. Xenobiotic Metab. Dispos. 15(Suppl), S259 (2000).
50. Würthwein G, Rehder S, Rohdewald P. Lipophilicity and receptor affinity of glucocorticoids. Pharm. Zig. Wiss. 137, 161-167 (1992).
51. Miller-Larsson A, Axelsson B, Brattsand R, Edsbäcker S, Ingelf J. Relative lipophilicity of budesonide, fluticasone propionate, mometasone fluroate, and ciclesonide. Preference of variable lipophilicity in airways versus systemic compartment. Am. J. Respir. Crit. Care Med. 22(Suppl. 45), A773 (2003).
52. Chapman K, Patel P, Boulet L et al. Efficacy and long-term safety of ciclesonide in asthmatic patients as demonstrated in a 52-week long study. Eur. Respir. J. 20(Suppl. 38), S373-S374 (2002) Abstract 2328.
53. Chapman K, D'Urzo AD, Oedekoven C, Steinijans V, Wurst W. Effects of ciclesonide versus placebo on lung function after 12 weeks of treatment in patients with asthma. Am. J. Respir. Crit. Care Med. 165(8), A767 (2002).
54. Drollmann A, Langdon C, Engelstätter R, Rathgeb F, Steinijans V, Wurst W. Ciclesonide is effective in the treatment of bronchial asthma. Eur. Respir. J. 18(Suppl. 33), S94 (2001).
55. Engelstätter R, Langdon C, Bethke T, Rathgeb F, Steinijans V, Wurst W. Efficacy of ciclesonide after 12-week treatment of bronchial asthma. Am. J. Respir. Crit. Care Med. 165(8), A766 (2002).
56. Hansel T, Engelstätter R, Benezet O et al. Once daily ciclesonide (80 μg or 320 μg) is equally effective as budenoside 200 μg given twice daily: a 12-week study in asthma patients. Eur. Respir. J. 22(Suppl. 45), 410 (2003).
57. Larsen B, Nielsen L, Engelstätter R, Steinijans V, Dahl R. Effect of ciclesonide on allergen challenge in subjects with bronchial asthma. Allergy 58(3), 207-212 (2003).
58. O'Connor B, Kilfeather S, Cheung D et al. Treatment of moderate to severe asthma with ciclesonide: a long-term investigation over 52 weeks. Eur. Respir. J. 20 (Suppl. 38), 406 (2002).
59. O'Connor B, Sips P, Engelstätter R, Steinijans V, Wurst W. Management of moderate to severe bronchial asthma by ciclesonide: a 12-week trial. Am. J. Respir. Crit. Care Med. 165(8), A767 (2002).
60. Ukena D, Biberger C, von Behren V et al. Ciclesonide significantly improves pulmonary function when compared with budesonide: A randomized 12-week study. Eur. Respir. J. 22(Suppl. 45), A2640 (2003).
61. Buhl R, Vinkler I, Magyar P et al. Once daily ciclesonide is as effective as fluticasone propionate given twice daily in treating patients with asthma. Am. J. Respir. Crit. Care Med. 169(7), A91 (2004).
62. Langdon C, Adler M, Mehra S, Drollmann A. Ciclesonide is effective in the treatment of mild to moderate asthma: a 12-week, placebo-controlled study. A worldwide approach to asthma: understanding treatment and prevention. 183, Abs. P2639 (2004).
63. Pedersen S, Garcia M, Manjra A, Vermeulen J, Theron I, Engelstäetter R. Ciclesonide is as effective as fluticasone propionate in the treatment of children with persistent asthma. Allergy 113(2), S921 (2004).
64. Engelstäetter R, Steinijans V, Wurst W. Low incidence of oropharyngeal adverse events in asthma patients created with ciclesonide: results from a pooled analysis. Am. J. Respir. Crit. Care Med. 169(7), A92 (2004).
65. Banerji D, Szwarcberg J, Fish J, Kundu S, Williams J, Hamedani P. Ciclesonide and placebo have similar incidence of oropharyngeal adverse events in adolescent/adult and pediatric asthma patients: results from pooled analyses. Allergy Asthma Proc. 25(3), P206 (2004).
66. Berger W, Mansfield L, Pinter C et al. Ciclesonide is well tolerated and has minimal oropharyngeal side effects at once-daily doses of 80 μg, 160 μg, and 320 μg in the treatment of patients with mild-to-moderate asthma. J. Allergy Clin. Immunol. 113(2 Suppl), S38 (2004).
67. Chapman K, Boulet L, D'Urzo A, Oedekoven C, Engelstäetter R. Long-term administration of ciclesonide is safe and well-tolerated in patients with persistent asthma. A worldwide approach to asthma: understanding treatment and prevention. 185, Abs. P232 (2004)
68. Korenblat P, Bernstein D, Fish J, Zhang P, Lloyd M, Banerji D. Ciclesonide HFA-MDI has a lower incidence of oral candidiasis than beclomethasone dipropionate HFA-MDI in patients with severe persistent asthma: results of a long-term study. Ann. Allergy Asthma Immunol. P171 (2005).
69. Lipworth BJ, Kaliner MA, LaForce CF et al. Ciclesonide at daily doses of 320 μg or 640 μg does not suppress HPA-axis in adults with mild-to-moderate persistent asthma. Ann. Allergy Asthma Immunol. (In Press).
70. Lee D, Lipworth B. Airway and systemic effects of hydrofluoroalkane formulations of high dose ciclesonide and fluticasone propionate in moderate, persistent asthma. Eur. Respir. J. 24(48), Abs. P3582 (2004).
71. Agertoft L, Pedersen S. Lower-leg growth rate and HPA-axis function in children with asthma during treatment with inhaled ciclesonide. J. Allergy Clin. Immunol. 113(Suppl. 2) Abs. 374 (2004).
72. Georgitis JW, Galant S, Lloyd BK et al. Once-daily ciclesonide does not cause HPA-axis suppression in pediatric asthma patients. American Academy of Pediatrics San Francisco, CA, USA Ocotber 9-13 (2004).
73. Allen DB, Mullen M, Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J. Allergy Clin. Immunol. 93(6), 967-976 (1994).
74. Nayak A, Nathan R, Williams J, Kundu S, Lloyd M, Banerji D. Ciclesonide does not suppress the hypothalamic-pituitary-adrenal axis function in patients with severe persistent asthma: results of a long-term study. Ann. Allergy Asthma Immunol. P164 (2005).